Osimertinib, a third-generation TKI, selectively and irreversibly inhibits many EGFR mutations (including ex19del, L858R, T790M) and is now first-line therapy for patients with EGFR-mutant NSCLC irrespective of T790M status [64]. Here, EGFR is linked to non-small cell lung carcinoma.